A re-examination of the impact of reference pricing on anti-hypertensive drug expenditures in British Columbia

Health Economics

Volumn 15, Issue 7, 2006, Pages 735-742

  Grootendorst, Paul ^a,b   Stewart, David ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c Brogan Inc   (Canada)

Author keywords

Drug costs; Pharmaceuticals; Reference pricing

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; FOSINOPRIL; LISINOPRIL; NICARDIPINE; NIFEDIPINE; QUINAPRIL; RAMIPRIL; VERAPAMIL;

ACCURACY; ARTICLE; CANADA; DRUG COST; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; HYPERTENSION; MATHEMATICAL COMPUTING; PATENT; PHARMACEUTICAL CARE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT;

ANTIHYPERTENSIVE AGENTS; BRITISH COLUMBIA; HEALTH EXPENDITURES; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MODELS, STATISTICAL; NATIONAL HEALTH PROGRAMS; REIMBURSEMENT MECHANISMS;

EID: 33745956031     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1103     Document Type: Article

References (13)

1. Ioannides-Demos LL, Ibrahim JE, McNeil JJ. Reference-based pricing schemes - effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics 2002; 20: 577-591.
2. Lopez-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy 2000; 54: 87-123.
3. Grootendorst PV, Dolovich LR, O'Brien BJ, Holbrook AM, Levy AR. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. Can Med Assoc J 2001; 165: 1011-1019.
4. Grootendorst P, Marshall J, Holbrook A, Dolovich L, O'Brien B, Levy A. The impact of differential cost sharing of non-steroidal anti-inflammatory agents on the use and costs of analgesic drugs. Health Serv Res 2005; 40: 1297-1317.
5. Hazlet TK, Blough DK. Health services utilization with reference drug pricing of histamine(2) receptor antagonists in British Columbia elderly. Med Care 2002; 40: 640-649.
6. Marshall JK, Grootendorst PV, O'Brien BJ, Dolovich LR, Holbrook AM, Levy AR. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. Can Med Assoc J 2002; 166: 1655-1662.
7. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med 2002; 346: 822-829.
8. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. Can Med Assoc J 2002; 166: 737-745.
9. Schneeweiss S, Dormuth C, Grootendorst P, Soumerai SB, Maclure M. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Med Care 2004; 42: 653-660.
10. Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther 2003; 74: 388-400.
11. Sketris IS, Metge CJ, Ross JL et al. The use of the World Health Organisation anatomical therapeutic chemical/defined daily dose methodology in Canada. Drug Inf J 2004; 38: 15-27.
12. Newey W, West K. A simple, positive semi-definite, heteroscedasticity and autocorrelation consistent covariance matrix. Econometrica 1987; 55: 703-708.
13. Grootendorst P, Dolovich L, Holbrook A, Levy A, O'Brien B. The impact of reference pricing of cardiovascular drugs on health care costs and health outcomes: evidence from British Columbia. SEDAP Research Paper No. 70, McMaster University, Hamilton Ont., 2002.